Business Wire

Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Breaking Cancer Immunotherapies

Del

Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170321005742/en/

As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI) technology leveraging a breakthrough approach to generate a series of fully human monoclonal antibodies (mAbs) against any therapeutic target, taking advantage of the affinity maturation processes performed in situ by B lymphocytes.

Pierre Fabre is an ideal partner for H-Immune to help us begin to realize the full potential of our science and IVI technology which we plan to exploit through multiple industry partnerships,” said Luc Boblet, PhD, Co-Founder and CEO of H-Immune. “This collaboration is designed to catalyze and create tremendous ongoing scientific and product development synergy by leveraging each company’s strengths and assets.”

Under the terms of the agreement, Pierre Fabre will have access to H-Immune’s IVI technology for three different discovery programs in the field of immuno-oncology.

This transaction strengthens Pierre Fabre’s position in the areas of immuno-oncology and novel cutting-edge biotherapeutics,” said Laurent Audoly, Head of R&D of Pierre Fabre Pharmaceuticals. “H-Immune is developing an antibody technology platform that we are looking forward to accessing as part of our ongoing efforts to identify and develop world-class novel cancer therapeutics. We believe this collaboration enhances the potential of both partners to deliver transformational therapies to patients in areas of significant unmet medical needs.”

Pierre Fabre has a longstanding commitment to development of pharmaceuticals through its Pierre Fabre Immunology Centre of excellence (CIPF) based in Saint-Julien-en-Genevois, France, which is dedicated to the identification, development and manufacturing of biologics.

The financial terms of the agreement, which include expertise contribution, R&D funding, and milestone payments to H-Immune, were not disclosed.

To find out more about Pierre Fabre, please go to www.pierre-fabre.com.

To find out more about H-Immune, please go to www.h-immune.com.

Contact information

Pierre Fabre Pharmaceuticals, Castres, France
Valérie Roucoules
PHONE: +33 1 49 10 83 84
Deputy Director of Media Relations -- Medicine and Health
E-MAIL: valerie.roucoules@pierre-fabre.com
or
H-Immune, Paris, France
Luc Boblet, PhD
PHONE: +33 6 49 17 45 11
Chief Executive Officer
E-MAIL: luc.boblet@h-immune.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 19:07Pressemelding

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

FINEOS Announces Three New Customers in the Cloud14.12.2017 15:57Pressemelding

FINEOS Corporation, the market leading provider of core systems for Life, Accident and Health (LA&H) insurance, today announced three new customers who have acquired FINEOS as a cloud service. The three new FINEOS customers, based in the US, Sweden and Canada respectively, have licenced FINEOS for their group insurance core processing needs. FINEOS is partnering with Amazon Web Services (AWS), the world’s largest IaaS cloud provider, to deliver the FINEOS Software as a Service (SaaS) offering. FINEOS Insurance Cloud is designed for the specific compliance and security needs of the LA&H industry. With simple subscription pricing, a FastTrack implementation approach, 24 x 7 support and continuous upgrades, the FINEOS Insurance Cloud is the way forward for LA&H insurance core systems. Speaking about the cloud, Gartner has said “By 2020, a Corporate ‘

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 15:52Pressemelding

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

Abdullah bin Zayed Honors Winners of the Al Hassan Bin Ali Award 2017 as Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies14.12.2017 15:19Pressemelding

His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, hosted a ceremony to honor the ‘Egyptian Family House’, winner of the Imam Al Hassan bin Ali Award 2017, represented by Dr. Mahmoud Hamdi Zaqzouq, Secretary General, and His Eminence Anba Ermia, Assistant Secretary General. Also present were H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim Societies. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005883/en/ Left to right: H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance, H.H Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim

Kymeta Announces Commercial Availability of KĀLO™ Mobile Internet Access Services14.12.2017 15:00Pressemelding

Kymeta—the communications company making good on the promise of global, mobile connectivity—and Intelsat S.A. (NYSE:I)—operator of the world’s first globalized network—have announced that Kymeta KĀLO internet access is now available with broad initial geographic coverage. Kymeta is redefining how satellite services are purchased with KĀLO internet services, and making mobile communications as easy to buy as a mobile phone plan. KĀLO internet services, powered by the IntelsatOne® Flex network, deliver broad connectivity when paired with the world’s only commercially available flat panel, electronically-steered satellite terminals from Kymeta as well as other satellite terminal solutions. Kymeta™ KyWay™ terminals and mTennau7 antenna subsystem modules open new markets for the satellite industry and allow organizations that require high-bandwidth mobile internet access to do busine

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion14.12.2017 13:47Pressemelding

BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada. “This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom